UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ Title of each class Trading Symbol(s) Name of each exchange on which registered Common Shares, no par value per share ACST NASDAQ Stock Market FORM 10-Q ______________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF T ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ Title of each class Trading Symbol(s) Name of each exchange on which registered Common Shares, no par value per share ACST NASDAQ Stock Market FORM 10-Q ______________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ Title of each class Trading Symbol(s) Name of each exchange on which registered Common Shares, no par value per share ACST NASDAQ Stock Market Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☐ FORM 10-Q ______________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended ...

Acasti Pharma Inc. (NASDAQ:ACST) Q4 2020 Earnings Conference Call June 29, 2020 10:30 AM ET Company Participants Alexandra Botie - IR, Crescendo Communications, LLC Jan D’Alvise - President and CEO Pierre Lemieux - COO, Chief Scientific Officer and Co-Founder Brian Groch - Chief Commercial Officer Jean-François Boily - VP, Finance Conference Call Participants Leland Gershell - Oppenheimer & Co. Mayank Mamtani - B. Riley FBR, Inc. Andre Uddin - Mackie Research Capital Corporation Nathan Weinstein - Aegis Cap ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 or FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35776 | --- | --- | --- | --- | |-----------------------------|------------------------------------------------------------------------ ...

Acasti Pharma Inc. (NASDAQ:ACST) Q3 2020 Results Conference Call February 14, 2020 1:00 PM ET Company Participants David Waldman - IR Jan D’Alvise - President and CEO Pierre Lemieux - COO, Chief Scientific Officer and Co-Founder Brian Groch - Chief Commercial Officer Jean-François Boily - VP, Finance Conference Call Participants Leland Gershell - Oppenheimer Toby Ma - Mackie Research Operator Ladies and gentlemen, Hello and thank you all for your patience and for joining today’s Acasti Pharma Third Quarter ...

Start Time: 13:00 January 1, 0000 1:40 PM ET Acasti Pharma Inc. (NASDAQ:ACST) Q2 2020 Earnings Conference Call November 13, 2019, 13:00 PM ET Company Participants Jan D’Alvise - President and CEO Jean-François Boily - VP, Finance Pierre Lemieux - Co-Founder, COO and CSO Brian Groch - CCO David Waldman - Crescendo Communications Conference Call Participants Nathan Weinstein - Aegis Capital Leland Gershell - Oppenheimer Robert Hazlett - BTIG Richard Ehrlich - JH Darbie Operator Good day, ladies and gentlemen ...